Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUVIX: Immune Response in Cervical Cancer
NCT03255252Phase 2Terminated
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jul 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin in Cervical Cancer (CC), sponsored by Institut du Cancer de Montpellier. Started Jul 2017; status: terminated.
02
Drugs
cisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03255252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255252.